TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9988803

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 44

Group type: COMPARATOR
Intervention: Dihydralazine
Number of subjects: 44
Study: 7556325

Group type: EXPERIMENTAL
Intervention: Heparin at 0.1, 0.25, 0.5 and 1 IU/ml added to TPN infusions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-heparinized control group
Number of subjects: 0
Study: 2272193

Group type: EXPERIMENTAL
Intervention: 1 mg flupenthixol dihydrochloride
Number of subjects: 153

Group type: COMPARATOR
Intervention: 75 mg dothiepin hydrochloride
Number of subjects: 153
Study: 7374100

Group type: EXPERIMENTAL
Intervention: Intraduodenal L-phenylalanine (100 mM)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Intraduodenal L-phenylalanine
Number of subjects: 32

Group type: COMPARATOR
Intervention: D-phenylalanine (50 mM)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: L-phenylalanine absorption rates
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Pancreatic secretion
Number of subjects: 32
Study: 30845039

Group type: EXPERIMENTAL
Intervention: Standard instrumentation (Groups 1 and 2)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Single-use patient-specific instrumentation (Group 3)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Reusable patient-specific instrumentation (Groups 4 and 5)
Number of subjects: 173
Study: 27941491

Group type: EXPERIMENTAL
Intervention: Low-intensity sprint training with blood flow restriction (pBFR)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low-intensity sprint training without blood flow restriction (control group)
Number of subjects: 24
Study: 25888011

Group type: EXPERIMENTAL
Intervention: Moderate hypoglycemia
Number of subjects: 2601

Group type: EXPERIMENTAL
Intervention: Severe hypoglycemia
Number of subjects: 2601

Group type: EXPERIMENTAL
Intervention: Multiple hypoglycemic events
Number of subjects: 2601
Study: 22934971

Group type: EXPERIMENTAL
Intervention: Portfolio-based professional development program (12 months)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Routine professional development programs (control group)
Number of subjects: 73
Study: 21232979

Group type: EXPERIMENTAL
Intervention: Gabapentin (1.2 g/d orally before and for 2 days after surgery)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 20054753

Group type: EXPERIMENTAL
Intervention: Rivastigmine, initial dose of 3 mg/day b.i.d., escalated to maximum tolerated dose in at least 4-week intervals.
Number of subjects: 54
Study: 17926612

Group type: EXPERIMENTAL
Intervention: Combined acupuncture and medicine group (acupuncture balance points 'Jiangya' and 'Shenbing' with small dose of hypotensor, Irbesartan)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Medication group (oral administration of Irbesartan and Fosinopril)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Combined acupuncture and medicine group
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 152
Study: 15178812

Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin) added to standard carboplatin/paclitaxel chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard carboplatin/paclitaxel chemotherapy alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bevacizumab with chemotherapy in patients with nonsquamous histologies
Number of subjects: 0
Study: 11338198

Group type: EXPERIMENTAL
Intervention: Kohonen feature map (KFM) for predicting alcohol withdrawal seizures
Number of subjects: 49

Group type: COMPARATOR
Intervention: High homocysteine (Hcy) levels on admission
Number of subjects: 49
Study: 10453539

Group type: EXPERIMENTAL
Intervention: Acute moderate isovolemic hemodilution
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study: 7889231

Group type: EXPERIMENTAL
Intervention: Transvenous electrode polarity configuration I (RV electrode as common cathode)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Transvenous electrode polarity configuration II (SVC electrode as common cathode)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Both configurations
Number of subjects: 21
Study: 2833178

Group type: EXPERIMENTAL
Intervention: CE therapy (CDDP plus etoposide)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: CE-AVN therapy (ACNU, VCR plus procarbazine)
Number of subjects: 27
Study: 30002323

Group type: EXPERIMENTAL
Intervention: Vegetarian diet
Number of subjects: 27

Group type: COMPARATOR
Intervention: Omnivorous diet
Number of subjects: 27
Study: 26658268

Group type: EXPERIMENTAL
Intervention: TIVA + ramosetron (0.3 mg ramosetron just before anaesthesia induction, remifentanil and propofol anaesthesia)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sevoflurane anaesthesia
Number of subjects: 72
Study: 25432143

Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% (TRAV)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Bimatoprost 0.01% (BIM)
Number of subjects: 81
Study: 22507665

Group type: COMPARATOR
Intervention: 900 mg of lithium
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 20446945

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (target systolic BP <140 mmHg within 1 hour, maintained for up to 7 days)
Number of subjects: 2800

Group type: COMPARATOR
Intervention: Conservative blood pressure management (target systolic BP <180 mmHg)
Number of subjects: 2800

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering
Number of subjects: 2800
Study: 18635505

Group type: EXPERIMENTAL
Intervention: Plain bupivacaine with epidural volume extension (PBE)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Plain bupivacaine (PB)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine (HB)
Number of subjects: 88
Study: 15787886

Group type: EXPERIMENTAL
Intervention: Folic acid 200 microg/day
Number of subjects: 2928

Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg/day
Number of subjects: 2928

Group type: EXPERIMENTAL
Intervention: Folic acid (high doses)
Number of subjects: 2928

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2928
Study: 12456032

Group type: EXPERIMENTAL
Intervention: Sorbent dialysis and standardized conventional medical treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ongoing medical treatment alone
Number of subjects: 20
Study: 10625865

Group type: EXPERIMENTAL
Intervention: PMS Symptom Management Program (PMS-SMP)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Waiting treatment group (control)
Number of subjects: 91
Study: 8746608

Group type: EXPERIMENTAL
Intervention: Azithromycin (3 or 5 days)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Clarithromycin (7 to 10 days)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 131

Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 131
Study: 2207304

Group type: EXPERIMENTAL
Intervention: 100 mg lomefloxacin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 200 mg lomefloxacin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 400 mg lomefloxacin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 600 mg lomefloxacin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 800 mg lomefloxacin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7445655

Group type: COMPARATOR
Intervention: Verapamil (0.1 mg/kg i.v.)
Number of subjects: 40

Group type: COMPARATOR
Intervention: D 600 (0.03 mg/kg i.v.)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ro 11-1781 (1.0 mg/kg i.v.)
Number of subjects: 40
Study: 30666700

Group type: EXPERIMENTAL
Intervention: VAS203 (10 mg/kg body weight)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 28142347

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) - 3 sessions
Number of subjects: 43

Group type: COMPARATOR
Intervention: Corticosteroid injection - 80 mg methylprednisolone, 1 injection
Number of subjects: 43
Study: 27565625

Group type: EXPERIMENTAL
Intervention: Financial incentives for smoking cessation during pregnancy
Number of subjects: 492
Study: 24210453

Group type: EXPERIMENTAL
Intervention: Diode laser (970nm)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Surgical blade (control)
Number of subjects: 30
Study: 21392096

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg daily)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg daily)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg daily) plus Simvastatin (40 mg daily)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 19713268

Group type: EXPERIMENTAL
Intervention: Daily movement training
Number of subjects: 26

Group type: COMPARATOR
Intervention: Daily social training
Number of subjects: 26
Study: 17539268

Group type: EXPERIMENTAL
Intervention: Regimen-A: 300 mg DHA followed by 750 mg MQ and 300 mg DHA 6 and 24 hours later
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Regimen-B: 300 mg DHA followed by 300 mg DHA and 750 mg MQ at 24 hours
Number of subjects: 12
Study: 15126524

Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitor (LAF237); 100 mg daily, n = 18
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo, n = 19
Number of subjects: 37
Study: 11274902

Group type: EXPERIMENTAL
Intervention: Insulin plus sulodexide (IS)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Insulin plus placebo (IP)
Number of subjects: 18
Study: 9607373

Group type: COMPARATOR
Intervention: 50 mg mibefradil
Number of subjects: 0

Group type: COMPARATOR
Intervention: 100 mg mibefradil
Number of subjects: 0
Study: 7521713

Group type: EXPERIMENTAL
Intervention: Choline magnesium trisalicylate (CMT) 1500 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Choline magnesium trisalicylate (CMT)
Number of subjects: 26
Study: 2683326

Group type: EXPERIMENTAL
Intervention: Cefixime (400 mg tablet once daily)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Trimethoprim (160 mg)/sulfamethoxazole (800 mg, one tablet every 12 hours)
Number of subjects: 106
Study: 821573

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy during surgical treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: No antibiotic therapy during surgical treatment
Number of subjects: 0
Study: 30345864

Group type: EXPERIMENTAL
Intervention: sildenafil citrate 20 mg orally three times a day, in addition to fish oil and zinc supplementation
Number of subjects: 46

Group type: COMPARATOR
Intervention: placebo (tablets similar to sildenafil)
Number of subjects: 46
Study: 30596830

Group type: EXPERIMENTAL
Intervention: Exposure to conflicting information about mammography (no, low, medium, or high conflict)
Number of subjects: 1474

Group type: EXPERIMENTAL
Intervention: High level of exposure to conflicting information
Number of subjects: 1474

Group type: EXPERIMENTAL
Intervention: Socioeconomic position
Number of subjects: 1474
Study: 27484290

Group type: EXPERIMENTAL
Intervention: Fludarabine and cyclophosphamide (FC)
Number of subjects: 0
Study: 26252751

Group type: EXPERIMENTAL
Intervention: FMD with CHX
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: FMD with AZ
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: QS with CHX
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: QS with AZ
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: FMD without adjuvants
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: QS without adjuvants
Number of subjects: 85
Study: 23447432

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 38
Study: 20886231

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 58

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 58
Study: 18183403

Group type: EXPERIMENTAL
Intervention: 1,350 ml of low-density barium (VoLumen)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 900 ml of low-density barium (VoLumen) and 450 ml of water
Number of subjects: 80
Study: 17058279

Group type: EXPERIMENTAL
Intervention: Palivizumab prophylaxis in Calgary (Post)
Number of subjects: 2033

Group type: COMPARATOR
Intervention: No palivizumab prophylaxis in Edmonton (Control)
Number of subjects: 2033

Group type: EXPERIMENTAL
Intervention: Palivizumab prophylaxis in Calgary for moderate-risk infants
Number of subjects: 2033
Study: 15575828

Group type: EXPERIMENTAL
Intervention: Tono-Pen
Number of subjects: 138

Group type: COMPARATOR
Intervention: Goldmann tonometer
Number of subjects: 138
Study: 11106051

Group type: EXPERIMENTAL
Intervention: Study group (preterm infants with apnoeas)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (normal controls)
Number of subjects: 36
Study: 9088654

Group type: EXPERIMENTAL
Intervention: Oral cow milk challenge (DBPCFC)
Number of subjects: 83
Study: 1545355

Group type: EXPERIMENTAL
Intervention: 155-mg oral tablet of hydroxychloroquine
Number of subjects: 9

Group type: COMPARATOR
Intervention: 155-mg iv infusion of racemic hydroxychloroquine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Deconvolution methods (staircase, delta function, least squares)
Number of subjects: 9
Study: 3903646

Group type: EXPERIMENTAL
Intervention: NIAID vaccine
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: BIVS vaccine
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Vaccine + hepatitis B immune globulin
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 30607062

Group type: EXPERIMENTAL
Intervention: Professional commitment assessment
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Perceived maternal health goal scale assessment
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Factors associated with professional commitment
Number of subjects: 442
Study: 28276210

Group type: EXPERIMENTAL
Intervention: 1-hour group education program with parents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 25362672

Group type: EXPERIMENTAL
Intervention: Rapid blood withdrawal (5 seconds)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Slow blood withdrawal (1 to 2 minutes)
Number of subjects: 50
Study: 22545593

Group type: EXPERIMENTAL
Intervention: Polyester braided thread (Mersilene™ or Ethibond™)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Mersilene tape™
Number of subjects: 138
Study: 20717750

Group type: EXPERIMENTAL
Intervention: Goal hemoglobin (HGB) concentration of at least 11.5 g/dl
Number of subjects: 44

Group type: COMPARATOR
Intervention: Goal hemoglobin (HGB) concentration of at least 10 g/dl
Number of subjects: 44
Study: 18311494

Group type: EXPERIMENTAL
Intervention: nCPAP alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: nCPAP and NML
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: nCPAP and HH
Number of subjects: 18
Study: 16086946

Group type: EXPERIMENTAL
Intervention: Fixed combination of travoprost 0.004%/timolol 0.5% once daily
Number of subjects: 403

Group type: COMPARATOR
Intervention: Concomitant travoprost 0.004% every evening + timolol 0.5% every morning
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Fixed combination of travoprost 0.004%/timolol 0.5%
Number of subjects: 403

Group type: COMPARATOR
Intervention: Concomitant travoprost + timolol
Number of subjects: 403
Study: 12451188

Group type: EXPERIMENTAL
Intervention: IFNbeta‐1a 44 micro g subcutaneously three times weekly (tiw)
Number of subjects: 677

Group type: COMPARATOR
Intervention: IFNbeta‐1a 30 micro g IM once weekly (qw)
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: IFNbeta‐1a 44 micro g tiw
Number of subjects: 677

Group type: COMPARATOR
Intervention: IFNbeta‐1a 30 micro g qw
Number of subjects: 677
Study: 11044464

Group type: EXPERIMENTAL
Intervention: LNG-IUS treatment for 6 months
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: LNG-IUS treatment for 12 months
Number of subjects: 67
Study: 8960647

Group type: EXPERIMENTAL
Intervention: 2 meals per day (2M group)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 6 meals per day (6M group)
Number of subjects: 12
Study: 1332987

Group type: EXPERIMENTAL
Intervention: Hydroxylapatite particles implantation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no implant)
Number of subjects: 10
Study: 4015741

Group type: EXPERIMENTAL
Intervention: Suprofen 200 mg/ml intravenous injection or infusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30066171

Group type: EXPERIMENTAL
Intervention: Subcostal approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intercostal approach
Number of subjects: 0
Study: 28735835

Group type: EXPERIMENTAL
Intervention: Scheduled second-look endoscopy (EGD) 24 to 36 hours after initial hemostasis
Number of subjects: 319

Group type: COMPARATOR
Intervention: Initial endoscopic hemostasis without scheduled second-look EGD
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Scheduled second-look endoscopy (EGD)
Number of subjects: 319
Study: 26439431

Group type: EXPERIMENTAL
Intervention: Bone marrow non-hematopoietic stem cells (NHBMSC) with cyclosporine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bone marrow non-hematopoietic stem cells (NHBMSC) without cyclosporine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Both groups (NHBMSC with and without cyclosporine)
Number of subjects: 14
Study: 24423366

Group type: EXPERIMENTAL
Intervention: Daily supplementation with 70 μg (2800 IU) cholecalciferol for 52 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Identical placebo for 52 weeks
Number of subjects: 46
Study: 22885606

Group type: EXPERIMENTAL
Intervention: Headphones
Number of subjects: 28

Group type: COMPARATOR
Intervention: No headphones (Control)
Number of subjects: 28
Study: 20417427

Group type: EXPERIMENTAL
Intervention: Transcervical resection of the polyp
Number of subjects: 150

Group type: COMPARATOR
Intervention: Observation for 6 months
Number of subjects: 150
Study: 18414870

Group type: EXPERIMENTAL
Intervention: Neutral oral contrast agent (3% mannitol)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Positive oral contrast medium
Number of subjects: 100
Study: 15781099

Group type: EXPERIMENTAL
Intervention: Sunflower seed oil
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Aquaphor
Number of subjects: 497

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 497
Study: 14623527

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anastrozole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exemestane
Number of subjects: 0
Study: 10559527

Group type: EXPERIMENTAL
Intervention: Red wine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Beer
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Spirits
Number of subjects: 11

Group type: COMPARATOR
Intervention: Water
Number of subjects: 11
Study: 8880676

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (5 or more treatments)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (4 or fewer treatments or refused)
Number of subjects: 77
Study: 29656600

Group type: EXPERIMENTAL
Intervention: Sucroferric oxyhydroxide (SFOH) 1.0-3.0 g/day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sevelamer 2.4-14.4 g/day
Number of subjects: 100
Study: 27151071

Group type: EXPERIMENTAL
Intervention: Virtual reality cognitive therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Virtual reality exposure
Number of subjects: 30
Study: 23772990

Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 1582

Group type: COMPARATOR
Intervention: Spontaneous
Number of subjects: 1582
Study: 23301470

Group type: EXPERIMENTAL
Intervention: Acupoint autohemotherapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Loratadine tablets (western medication)
Number of subjects: 45
Study: 20845511

Group type: EXPERIMENTAL
Intervention: HDR‐ILBT group (n = 17)
Number of subjects: 36

Group type: COMPARATOR
Intervention: EBRT group (n = 19)
Number of subjects: 36
Study: 17697063

Group type: EXPERIMENTAL
Intervention: Insulin glargine (once-daily)
Number of subjects: 819
Study: 16274417

Group type: EXPERIMENTAL
Intervention: Flecainide (1.5 mg/kg per day)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Flecainide (3.0 mg/kg per day)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 12165681

Group type: EXPERIMENTAL
Intervention: rhGH 0.09 IU.kg BW(‐1).d(‐1) for 6 days a week (A trial)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: rhGH 0.09 IU.kg BW(‐1).d(‐1) for 3 days a week (B trial)
Number of subjects: 7
Study: 10219654

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine and famotidine (H1- and H2-receptor antagonist)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Hydroxyzine (H1-receptor antagonist)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 80
Study: 7529522

Group type: EXPERIMENTAL
Intervention: MIP (mitomycin 6 mg m‐2, ifosfamide 3 g m‐2, cisplatinum 80 mg m‐2 on day 1 every 28 days)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: MIP-IFN (MIP and interferon alpha‐2b 3 MU s.c. three times a week)
Number of subjects: 93

Group type: COMPARATOR
Intervention: PC (cisplatinum 60 mg m‐2 and carboplatin 400 mg m‐2 on day 1 every 28 days)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 93
Study: 2212185

Group type: EXPERIMENTAL
Intervention: short-term dynamically oriented individual therapy
Number of subjects: 144

Group type: COMPARATOR
Intervention: low QOR control group
Number of subjects: 144
Study: 727423

Group type: EXPERIMENTAL
Intervention: Calcium gluconate (10 ml 10%)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Calcium chloride (10 ml 5.5%)
Number of subjects: 44
Study: 31366332

Group type: EXPERIMENTAL
Intervention: Perforation with application of autologous blood
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Perforation with application of dextrose
Number of subjects: 165

Group type: COMPARATOR
Intervention: Perforation only
Number of subjects: 165
Study: 27890156

Group type: EXPERIMENTAL
Intervention: Phase change cooling (PCC) garment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 20
Study: 26525549

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicines for nourishing yin, supplementing qi, and activating blood combined with hydroxychloroquine sulfate tablets
Number of subjects: 70

Group type: COMPARATOR
Intervention: Hydroxychloroquine sulfate tablets alone
Number of subjects: 70
Study: 24225205

Group type: EXPERIMENTAL
Intervention: Home medication review (HMR) and medication management (MM) conducted by Dementia Care Manager (DCM) in cooperation with pharmacists and general practitioners.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training and provision of regularly updated information to pharmacists involved in the MM.
Number of subjects: 0